Led by $230m acquisition of M.I.Tech, Asia-Pacific’s medical devices industry saw a drop of 26.05% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 22 cross border deals worth $689.9m were announced for the region during Q2 2022, against the last four-quarter average of 29.75 deals.
Of all the deal types, venture financing saw most activity in Q2 2022 with 13 deals, representing a 59.1% share for the region.
In second place was M&A with seven deals, followed by private equity deals with two transactions, respectively capturing a 31.8% and 9.1% share of the overall cross border deal activity for the quarter.
In terms of value of cross border deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $251.77m, while M&A and private equity deals totalled $230m and $208.13m, respectively.
Asia-Pacific medical devices industry cross border deals in Q2 2022: Top deals
The top five medical devices cross border deals accounted for an 82.5% share of the overall value during Q2 2022.
The combined value of the top five cross border deals stood at $569.13m, against the overall value of $689.9m recorded for the quarter.
1) Boston Scientific $230m acquisition deal for 64% stake in M.I.Tech
2) The $140.13m private equity of Genea by Liverpool Partners
3) Globis Capital Partners &,Incubate Fund,SoftBank Vision Fund 2 and World Innovation Lab (WiL fund) $70m venture financing deal with AI Medical Service
4) The $68m private equity of Accumax Lab Technology by Creador Sdn and India Life Sciences Fund III
5) Alkemi Venture Partners,Chiratae Ventures,HealthQuad,LC Nueva AIF,LeapFrog Investments,Schroders and Spark Growth Ventures $61m venture financing deal with Redcliffe Lifetech